(Ethinylestradiol + segesterone acetate) ER is a Small Molecule owned by Population Council, and is involved in 9 clinical trials, which were completed.
Nestorone is a synthetic progestin, (segesterone) acts as progesterone receptor agonist. It exhibits strong progestational activity, combined with lack of androgenic, estrogenic and glucocorticoid-like activities. Estradiol acts as estrogen receptor agonist. Estrogen plays a role in female fertility and specifically ovulation. It checks pregnancy by inhibiting ovulation. Progestin works by suppressing ovulation, thickening cervical mucus, and thinning the endometrium.
The revenue for (Ethinylestradiol + segesterone acetate) ER is expected to reach a total of $6.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Ethinylestradiol + segesterone acetate) ER NPV Report.
(Ethinylestradiol + segesterone acetate) ER is currently owned by Population Council. TherapeuticsMD is the other company associated in development or marketing of (Ethinylestradiol + segesterone acetate) ER.
(Ethinylestradiol + segesterone acetate) ER Overview
Ethinylestradiol and Segesterone acetate (Annovera) is a fixed dose combination, acts as an contraceptive agent. It is formulated as extended release implant (ring) for vaginal route of administration. Annovera is indicated to prevent pregnancy in females.
TherapeuticsMD is an innovative pharmaceutical company. It develops products to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company’s major products portfolio includes segesterone acetate and ethinyl estradiol, estradiol and progesterone capsules, prenatal vitamins, estradiol vaginal inserts. The company sells its products under the various brands name of VitamedMD, BocagreenMD, Annovera, Bijuva, vitaPearl, vitaTrue, vitaMedMD RediChew Rx, vitaMedMD One Rx, FOLMAX, pur-DHA, FePlus, Plant Pure Omega-3 DHA and Imvexxy. TherapeuticsMD is headquartered in Boca Raton, Florida, the US.
The company reported revenues of (US Dollars) US$87 million for the fiscal year ended December 2021 (FY2021), an increase of 34% over FY2020. The operating loss of the company was US$139.8 million in FY2021, compared to an operating loss of US$155.5 million in FY2020. The net loss of the company was US$172.4 million in FY2021, compared to a net loss of US$183.5 million in FY2020. The company reported revenues of US$20.9 million for the third quarter ended September 2022, a decrease of 26.8% over the previous quarter.
Quick View – (Ethinylestradiol + segesterone acetate) ER
|Highest Development Stage|